Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX2 | Q96LB1 | 5/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 11/20 | 0.62 |
| ▸ | OPRK1 | P41145 | 7/20 | 0.62 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.62 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.62 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.62 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5108263 | 1.00 | MRGPRX2 (1.00) | MRGPRX2OPRM1OPRK1OPRD1ADRB1 | |
| Hydrochloric Acid SCHEMBL8168636 | 0.99 | MRGPRX2 (0.98) | MRGPRX2OPRM1OPRK1OPRD1ADRB1 | |
| SCHEMBL20983505 | 0.90 | MRGPRX2 (0.82) | MRGPRX2OPRM1OPRK1OPRD1ADRB1 | |
| Methoxymethane SCHEMBL27466715 | 0.89 | MRGPRX2 (0.94) | MRGPRX2OPRM1OPRK1OPRD1 | |
| SCHEMBL29449917 | 0.88 | MRGPRX2 (1.00) | MRGPRX2OPRM1OPRK1OPRD1 | |
| SCHEMBL154048 | 0.88 | MRGPRX2 (1.00) | MRGPRX2OPRM1OPRK1OPRD1 | |
| SCHEMBL29583693 | 0.88 | MRGPRX2 (1.00) | MRGPRX2OPRM1OPRK1OPRD1 | |
| SCHEMBL20522476 | 0.88 | MRGPRX2 (0.78) | MRGPRX2OPRM1OPRK1OPRD1ADRB1 | |
| Hydrochloric Acid SCHEMBL27754570 | 0.87 | MRGPRX2 (0.98) | MRGPRX2OPRM1OPRK1OPRD1 | |
| SCHEMBL6157352 | 0.87 | MRGPRX2 (0.77) | MRGPRX2OPRM1OPRK1OPRD1ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137675-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS TO TREAT DRUG OVERDOSE | ENALARE THERAPEUTICS INC (US) | 2026-05-21 | — | — | US | disclosed |
| US-12544369-B2 | Methods and pharmaceutical compositions to treat drug overdose | ENALARE THERAPEUTICS INC. (US) | 2026-02-10 | — | — | US | disclosed |
| US-20250262218-A1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR STIMULATING RESPIRATION | Auros Pharma LLC | 2025-08-21 | — | — | US | disclosed |
| WO-2025080559-A1 | METHODS AND COMPOSITIONS FOR TREATING DRUG OVERDOSE | ENALARE THERAPEUTICS INC. (US) | 2025-04-17 | — | — | WO | disclosed |
| US-20250114370-A1 | METHODS AND COMPOSITIONS FOR TREATING DRUG OVERDOSE | ENALARE THERAPEUTICS INC (US) | 2025-04-10 | — | — | US | disclosed |
| EP-4504206-A2 | RESPIRATORY STIMULANT NASAL FORMULATIONS | Enalare Therapeutics Inc. (US) | 2025-02-12 | — | — | EP | disclosed |
| WO-2024211329-A2 | DEVICES AND METHODS OF MAKING AND USE THEREOF | THE METHODIST HOSPITAL (US) | 2024-10-10 | — | — | WO | disclosed |
| US-20230310440-A1 | RESPIRATORY STIMULANT NASAL FORMULATIONS | ENALARE THERAPEUTICS INC. | 2023-10-05 | — | — | US | disclosed |
| WO-2023192602-A2 | RESPIRATORY STIMULANT NASAL FORMULATIONS | ENALARE THERAPEUTICS INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| US-20220241268-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS TO TREAT DRUG OVERDOSE | ENALARE THERAPEUTICS INC. | 2022-08-04 | — | — | US | disclosed |
| CN-114173872-A | Methods and pharmaceutical compositions for treating drug overdose | 依那拉治疗股份有限公司 | 2022-03-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12544369-B2 | Methods and pharmaceutical compositions to treat drug overdose | OPRK1, OPRD1, OPRM1 | MRGPRX2 379/4885OPRM1 3/4885OPRK1 1/4885 |
| US-20260137675-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS TO TREAT DRUG OVERDOSE | ADRA2B, ADRB1, ADRB2 | MRGPRX2 178/4885OPRM1 6/4885OPRK1 7/4885 |
| US-20230310440-A1 | RESPIRATORY STIMULANT NASAL FORMULATIONS | ADRA2C, MTNR1B, MTNR1A | MRGPRX2 13/4885OPRM1 60/4885OPRK1 22/4885 |
| US-20220241268-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS TO TREAT DRUG OVERDOSE | OPRK1, OPRM1, ADRB1 | MRGPRX2 97/4885OPRM1 2/4885OPRK1 1/4885 |
| US-20250114370-A1 | METHODS AND COMPOSITIONS FOR TREATING DRUG OVERDOSE | ADRA2A, ADRA2C, OPRM1 | MRGPRX2 83/4885OPRM1 3/4885OPRK1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.